Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study
- DOI
- 10.1111/all.16351
- Published
- 2024-10-07
- Container
- Allergy
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/all.16351,
title = {Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study},
author = {Avner Reshef and Connie Hsu and Constance H. Katelaris and Philip H. Li and Markus Magerl and Keiko Yamagami and Mar Guilarte and Paul K. Keith and Jonathan A. Bernstein and John‐Philip Lawo and Harsha Shetty and Maressa Pollen and Lolis Wieman and Tim J. Craig and Unknown},
year = {2024},
journal = {Allergy},
doi = {10.1111/all.16351},
url = {https://doi.org/10.1111/all.16351}
}RIS
TY - JOUR TI - Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study AU - Avner Reshef AU - Connie Hsu AU - Constance H. Katelaris AU - Philip H. Li AU - Markus Magerl AU - Keiko Yamagami AU - Mar Guilarte AU - Paul K. Keith AU - Jonathan A. Bernstein AU - John‐Philip Lawo AU - Harsha Shetty AU - Maressa Pollen AU - Lolis Wieman AU - Tim J. Craig AU - Unknown PY - 2024 JO - Allergy DO - 10.1111/all.16351 UR - https://doi.org/10.1111/all.16351 ER -
APA
Reshef, A., Hsu, C., Katelaris, C. H., Li, P. H., Magerl, M., Yamagami, K., Guilarte, M., Keith, P. K., Bernstein, J. A., Lawo, J., Shetty, H., Pollen, M., Wieman, L., Craig, T. J., & Unknown (2024). Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study. Allergy. https://doi.org/10.1111/all.16351
Source records
- crossref · retrieved 2026-09-27T06:11:10.200Z